R
Rallybio Corp
NASDAQ:RLYB
Rallybio Corp
NASDAQ:RLYB
Price:
8.22
USD
-1.32%
Market Closed
Market Cap:
$43.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
R
|
Rallybio Corp
NASDAQ:RLYB
|
US |
|
Tamron Co Ltd
TSE:7740
|
JP |
|
Thunder Tiger Corp
TWSE:8033
|
TW |
|
NK Lukoil PAO
OTC:LUKOY
|
RU |
|
Silver Mines Ltd
ASX:SVL
|
AU |
|
State Street Corp
NYSE:STT
|
US |
|
Vivimed Labs Ltd
NSE:VIVIMEDLAB
|
IN |
|
Acciona SA
OTC:ACXIF
|
ES |
|
Willas-Array Electronics (Holdings) Ltd
HKEX:854
|
HK |
|
Elekta AB (publ)
STO:EKTA B
|
SE |
|
K
|
Kobay Technology Bhd
KLSE:KOBAY
|
MY |
|
Kestrel Gold Inc
XTSX:KGC
|
CA |
|
V
|
Vigo Photonics SA
WSE:VGO
|
PL |
|
Sompo Holdings Inc
TSE:8630
|
JP |
Income Statement
Earnings Waterfall
Rallybio Corp
Rallybio Corp
Income Statement
Rallybio Corp
Rallybio Corp
Currency: USD
| Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+100%
|
1
+6%
|
1
+33%
|
1
-10%
|
1
-11%
|
1
+27%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(33)
|
(46)
|
(47)
|
(54)
|
(63)
|
(68)
|
(72)
|
(74)
|
(75)
|
(79)
|
(80)
|
(78)
|
(71)
|
(61)
|
(51)
|
(44)
|
(39)
|
(34)
|
|
| Selling, General & Administrative |
(13)
|
(19)
|
(22)
|
(25)
|
(27)
|
(27)
|
(28)
|
(27)
|
(27)
|
(25)
|
(25)
|
(23)
|
(21)
|
(20)
|
(17)
|
(17)
|
(16)
|
(14)
|
|
| Research & Development |
(21)
|
(27)
|
(26)
|
(29)
|
(36)
|
(41)
|
(44)
|
(47)
|
(48)
|
(54)
|
(55)
|
(55)
|
(50)
|
(42)
|
(34)
|
(27)
|
(23)
|
(20)
|
|
| Operating Income |
(33)
N/A
|
(46)
-37%
|
(47)
-3%
|
(54)
-15%
|
(63)
-16%
|
(68)
-8%
|
(72)
-6%
|
(74)
-3%
|
(75)
-1%
|
(79)
-5%
|
(80)
-2%
|
(78)
+3%
|
(71)
+9%
|
(60)
+15%
|
(51)
+16%
|
(44)
+15%
|
(38)
+12%
|
(33)
+13%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
1
|
2
|
3
|
5
|
6
|
6
|
6
|
5
|
5
|
4
|
4
|
3
|
2
|
2
|
|
| Non-Reccuring Items |
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
|
| Total Other Income |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
23
|
23
|
|
| Pre-Tax Income |
(35)
N/A
|
(47)
-36%
|
(48)
-3%
|
(55)
-13%
|
(63)
-15%
|
(67)
-6%
|
(69)
-4%
|
(71)
-2%
|
(71)
N/A
|
(75)
-6%
|
(76)
-2%
|
(74)
+3%
|
(66)
+10%
|
(58)
+13%
|
(47)
+18%
|
(41)
+13%
|
(14)
+66%
|
(9)
+36%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(35)
|
(47)
|
(48)
|
(55)
|
(63)
|
(67)
|
(69)
|
(71)
|
(71)
|
(75)
|
(76)
|
(74)
|
(66)
|
(58)
|
(47)
|
(41)
|
(14)
|
(9)
|
|
| Net Income (Common) |
(35)
N/A
|
(47)
-36%
|
(48)
-3%
|
(55)
-13%
|
(63)
-15%
|
(67)
-6%
|
(69)
-4%
|
(71)
-2%
|
(71)
N/A
|
(75)
-6%
|
(76)
-2%
|
(74)
+3%
|
(66)
+10%
|
(58)
+13%
|
(47)
+18%
|
(41)
+13%
|
(14)
+66%
|
(9)
+36%
|
|
| EPS (Diluted) |
-10.05
N/A
|
-14.73
-47%
|
-12.73
+14%
|
-14.3
-12%
|
-16.34
-14%
|
-16.75
-3%
|
-13.8
+18%
|
-13.97
-1%
|
-13.91
+0%
|
-14.75
-6%
|
-14.96
-1%
|
-13.35
+11%
|
-11.88
+11%
|
-10.61
+11%
|
-8.47
+20%
|
-7.34
+13%
|
-2.5
+66%
|
-1.59
+36%
|
|
Switch to:
Switch to:
See Also
Discover More
